Fluphenazine

Pronunciation: floo-FEN-uh-zeen.

Generic name
fluphenazine
Drug class
First-generation (typical) antipsychotic, phenothiazine derivative
Form
Tablets (1 mg, 2.5 mg, 5 mg, 10 mg), oral concentrate solution, and long-acting decanoate injection (25 mg/mL)
Route
Oral (tablet, concentrate solution) or long-acting intramuscular/subcutaneous injection (decanoate)
Legal status
Prescription-only

Availability and supply rules vary by country

Trade names by country: United States · Canada

Australia: · Full directory

What fluphenazine is and how it works

Fluphenazine is a high-potency, first-generation antipsychotic used to manage psychotic disorders such as schizophrenia. It is available as oral tablets or solution for regular daily dosing, and as a long-acting decanoate injection given every few weeks for people who need prolonged antipsychotic therapy. (1)

Fluphenazine carries a genuine FDA boxed warning: it is not approved, and should not be used, for psychosis related to dementia in older adults, because of an increased risk of death in this specific group. It can also cause movement disorders (some potentially irreversible) and a rare but life-threatening reaction called neuroleptic malignant syndrome. Take only as prescribed and never stop or change the dose without your prescriber's guidance.

Mechanism of action: how fluphenazine works

Fluphenazine is a high-potency phenothiazine antipsychotic that blocks central dopamine D2 receptors, producing antipsychotic effects along with a relatively high propensity (compared with lower-potency phenothiazines) for extrapyramidal side effects. (1)

What fluphenazine is used for

Psychotic disorders (e.g. schizophrenia)

Used to manage the manifestations of psychotic disorders. It has not been shown effective for behavioural complications in people with intellectual disability, and is not approved for dementia-related psychosis in older adults. (1)

Long-acting maintenance therapy (decanoate injection)

The decanoate injection is used for people who need prolonged antipsychotic treatment, giving a steady effect over several weeks between injections instead of daily oral dosing. (2)

Before taking fluphenazine

Do not take / not appropriate for

  • Do not use if you have suspected or established subcortical brain damage. (all countries) (1)
  • Do not use together with large doses of hypnotic (sleep-inducing) medicines. (all countries) (1)
  • Do not use if you are in a comatose or severely depressed state (e.g. from CNS depressants). (all countries) (1)
  • Do not use if you have pre-existing blood cell disorders (blood dyscrasias) or liver damage. (all countries) (1)
  • Do not use if you have a known hypersensitivity to fluphenazine or other phenothiazine medicines. (all countries) (1)
  • This medicine is not approved for treating psychosis related to dementia in older adults. (all countries) (1)

Tell your clinician about

  • If you or a family member has had tardive dyskinesia or neuroleptic malignant syndrome with any antipsychotic before.
  • If you have a history of low white blood cell counts, liver disease, seizures, heart disease, or low blood pressure.
  • All other medicines, especially other sedating or CNS-depressant medicines and alcohol.
  • Whether you are pregnant, planning pregnancy, or breastfeeding.
  • If you are an older adult with dementia -- this medicine is not approved for dementia-related psychosis and carries a boxed warning of increased death risk in that specific situation.
(1)

How to take fluphenazine

  • Take exactly as prescribed by your doctor; do not change your dose or stop taking fluphenazine without medical guidance.
  • The decanoate injection is given by a healthcare professional as a long-acting depot, typically every few weeks -- do not attempt to self-administer.
  • Avoid alcohol, which can add to drowsiness and other effects.
  • Be careful with driving or operating machinery until you know how this medicine affects you.
(1) (2)

Procedures and treatment changes

Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1) (2) (3) (4) (5) (6) (7)

Missed dose

Contact your prescriber or care team for guidance if you miss a dose of oral fluphenazine, or if you miss a scheduled decanoate injection appointment. do not take an extra dose or adjust your own dose or schedule.

Overdose

Seek emergency medical help immediately if you think you or someone else has taken too much fluphenazine, or if severe drowsiness, muscle rigidity, high fever, very low blood pressure, an irregular heartbeat, or loss of consciousness occurs. (1)

Side effects

Side effects and their urgency vary; report severe, persistent, or concerning symptoms.

Drowsiness.

What to notice: Drowsiness.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1)

Dry mouth, constipation, and blurred vision.

What to notice: Dry mouth, constipation, and blurred vision.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1)

Low blood pressure or changes in blood pressure.

What to notice: Low blood pressure or changes in blood pressure.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1)

Weight changes.

What to notice: Weight changes.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1)

Menstrual irregularities or breast enlargement (gynecomastia).

What to notice: Menstrual irregularities or breast enlargement (gynecomastia).

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1)

Serious warnings

Increased risk of death in elderly patients with dementia-related psychosis — boxed_warning

Symptoms: This is a population-level risk identified in clinical trials of antipsychotic medicines, not a specific symptom to watch for.

Action: Fluphenazine is not approved for dementia-related psychosis in older adults. If this medicine has been prescribed for an older adult with dementia, discuss this boxed warning directly with the prescribing clinician before continuing treatment. (1)

Tardive dyskinesia — high caution

Symptoms: Involuntary, repetitive movements of the face, tongue, or body (for example, lip smacking, tongue movements, or limb movements) that may develop during treatment or after it is reduced or stopped, and may be permanent.

Action: Contact your clinician promptly if these movements appear. Do not ask the prescriber about stopping it on your own -- your clinician will assess whether to adjust or change treatment. (1)

Neuroleptic malignant syndrome (NMS) — emergency

Symptoms: High fever, severe muscle stiffness, confusion or altered mental status, irregular pulse or blood pressure, fast heartbeat, and heavy sweating.

Action: This is a rare but potentially fatal reaction. Seek emergency medical help immediately -- NMS requires urgent medical assessment and, in hospital, immediate discontinuation of the antipsychotic under medical supervision. (1)

Signs of low white blood cell counts (blood dyscrasias) — high caution

Symptoms: Fever, sore throat, mouth sores, or unusual signs of infection.

Action: Contact your clinician promptly for blood testing -- fluphenazine has been associated with leukopenia and agranulocytosis. (1)

Interactions

  • Alcohol and other CNS depressants (sedatives, hypnotics) can add to drowsiness and should be used with caution or avoided. (1)
  • Concurrent large doses of hypnotic medicines are contraindicated with fluphenazine. (1)
  • Other medicines affecting liver function or blood counts may need closer monitoring alongside fluphenazine. (1)

Pregnancy, breastfeeding, kidney/liver function, age

Pregnancy

Safety has not been established. The possible hazards should be weighed against potential benefits by your prescriber. Antipsychotic exposure late in pregnancy (third trimester) has been associated with extrapyramidal symptoms and withdrawal effects in newborns. (1) (2) (3) (4) (5) (6) (7)

Breastfeeding

Discuss with your clinician; specific breastfeeding safety data were not detailed in the sources reviewed for this dossier. (1) (2) (3) (4) (5) (6) (7)

Elderly

Not approved for dementia-related psychosis, which carries a boxed warning for increased mortality in this specific population. When used for other approved indications, a lower starting dose (1-2.5 mg daily) is recommended, with close monitoring. (1) (2) (3) (4) (5) (6) (7)

Hepatic_impairment

Contraindicated in patients with pre-existing liver damage per the US label. (1) (2) (3) (4) (5) (6) (7)

Renal_impairment

No specific dose-adjustment schedule was described in the sources reviewed for this dossier; use with clinician-directed caution. (1) (2) (3) (4) (5) (6) (7)

Monitoring

Before starting

  • Baseline blood counts and liver function
  • Review for prior tardive dyskinesia or NMS with any antipsychotic
  • Assessment for dementia-related psychosis (contraindicated use)

During treatment

  • Periodic assessment for abnormal movements (tardive dyskinesia), including periodic dose reduction where clinically possible to aid early detection.
  • Prompt evaluation for fever, muscle rigidity, or altered mental status (possible NMS).
  • Blood counts if signs of infection or unusual bruising/bleeding occur.
  • Blood pressure monitoring, particularly in older adults or those prone to low blood pressure.
(1)

Storage

Store at room temperature, protected from light, out of reach of children. The decanoate injection is stored and administered by a healthcare professional.

Professional information

Clinician-facing context only, sourced from the current US FDA prescribing information; verify against the current full label before prescribing.

United States

Indication: Psychotic disorders

Dose summary: Oral: 2.5-10 mg/day initial in divided doses, usual maintenance 1-5 mg/day; elderly start 1-2.5 mg/day. Decanoate: individualised interval (typically every 2-4 weeks), amount based on response and prior oral requirement.

Renal context: No specific renal dose-adjustment schedule identified in the sources reviewed. (1) (2)

Mechanism of action

Hepatic guidance

Contraindicated with pre-existing liver damage; monitor liver function during treatment per the US label's general precautions.

Overdose note

No specific antidote; manage with supportive care, monitoring for hypotension, arrhythmia, extrapyramidal reactions, and CNS depression. (1)

Frequently asked questions

Is fluphenazine available in the US, UK, Europe, Canada, Australia, and New Zealand?

It is currently marketed in the United States, as both oral tablets/solution and the long-acting decanoate injection, under multiple manufacturers. In the United Kingdom, the medicine is reported to remain licensed, but the manufacturer discontinued supply of the decanoate depot injection (Modecate) around 2018 because of a global shortage of the active ingredient, not a safety concern. In Canada, Health Canada's own database confirms the decanoate injection (Modecate Concentrate) is cancelled post-market (last sold 2020). A direct search of Australia's TGA database found no currently registered fluphenazine product. Current status in the European Union and New Zealand could not be confirmed after genuine attempts and is disclosed here as unresolved rather than assumed. (1) (4) (5) (6)

Why does fluphenazine have a boxed warning?

Like other antipsychotic medicines, fluphenazine carries the FDA's strongest warning because clinical trials found elderly patients with dementia-related psychosis who were treated with antipsychotic drugs had a higher risk of death than those given a placebo. Fluphenazine is not approved for this use. (1)

What is tardive dyskinesia and can it be reversed?

It is a movement disorder involving involuntary, repetitive movements (such as lip smacking or limb movements) that can develop during or after antipsychotic treatment. It may be permanent in some people, which is why clinicians periodically reassess the need for continued treatment and the lowest effective dose. Contact your clinician promptly if you notice these movements -- do not ask the prescriber about stopping it yourself. (1)

What should I do if I think someone has neuroleptic malignant syndrome (NMS)?

NMS is a rare, potentially fatal reaction that can occur with antipsychotic medicines, causing high fever, severe muscle stiffness, confusion, and unstable blood pressure or heart rate. It is a medical emergency -- seek emergency care immediately rather than waiting to see if it improves. (1)

What is the mechanism of action of fluphenazine?

Fluphenazine is a high-potency phenothiazine antipsychotic that blocks central dopamine D2 receptors, producing antipsychotic effects along with a relatively high propensity (compared with lower-potency phenothiazines) for extrapyramidal side effects. (1)

What is the generic name of Fluphenazine?

The generic name is fluphenazine. (1) (2)

What class of drug is fluphenazine?

Fluphenazine is classed as: First-generation (typical) antipsychotic, phenothiazine derivative. (1) (2)

References

  1. FLUPHENAZINE HYDROCHLORIDE tablet, film coated -- full prescribing informationU.S. Food and Drug Administration / DailyMed (NIH), full prescribing information · United States · accessed 2026-07-31 · source 1
  2. FLUPHENAZINE DECANOATE injection, solution -- currently marketedU.S. Food and Drug Administration / DailyMed (NIH), Fresenius Kabi USA, LLC · United States · accessed 2026-07-31 · source 2
  3. Dr. Reddy's Laboratories announces the launch of Fluphenazine Hydrochloride Tablets USP in the U.S. marketDr. Reddy's Laboratories press release (business wire) · United States · accessed 2026-07-31 · source 3
  4. Fluphenazine decanoate (Modecate) discontinued -- manufacturer supply noticeUK NHS/prescriber advisory sources (Prescriber.org.uk; NHS Kent & Medway Partnership Trust formulary discontinuation notice), reporting the manufacturer's own discontinuation announcement · United Kingdom · accessed 2026-07-31 · source 4
  5. MODECATE CONCENTRATE (fluphenazine decanoate) -- Health Canada DPD entry, DIN 00755575Health Canada Drug Product Database (DPD) · Canada · accessed 2026-07-31 · source 5
  6. TGA eBS product database search for "fluphenazine" -- 0 documents returnedTherapeutic Goods Administration (TGA), Australia -- eBS Product Information database search · Australia · accessed 2026-07-31 · source 6
  7. The impact of fluphenazine withdrawal: a mirror-image studyIrish Journal of Psychological Medicine (Cambridge Core) -- peer-reviewed clinical report on fluphenazine withdrawal · Ireland (cited as representative of the multi-country pattern) · accessed 2026-07-31 · source 7

Brand names by country

Single-ingredient fluphenazine names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.

Priority countries

United States

  • Fluphenazine Hydrochoride10 mg, 1 mg, 2.5 mg, 5 mg · rising pharma holdings, inc.

Canada

  • FLUPHENAZINE OMEGA
  • MODECATE CONCENTRATE
  • PMS-FLUPHENAZINE DECANOATE INJ
View brands in additional countries.

This page provides general reference information about fluphenazine and is not a substitute for advice from the prescriber managing your treatment. All dosing and treatment decisions should be made with your prescriber. Availability varies by country and has genuinely changed in recent years; confirm current local availability with a pharmacist or prescriber.

Related medicines

Related conditions